International Stem Cell Corporation Reports Positive Pre-Clinical Trial Results From Human Corneal Epithelial Cells

Press Release Source: International Stem Cell Corporation International Stem Cell Corporation Reports Positive Pre-Clinical Trial Results From Human Corneal Epithelial Cells Trials Designed to Improve Laser Eye Surgery Outcomes On Wednesday May 27, 2009, 8:30 am EDT OCEANSIDE, Calif.--()--International Stem Cell Corporation (OTCBB:ISCO), the first company to perfect a method of creating human “parthenogenetic” stem cells from unfertilized eggs, has received positive early results from animal trials designed to improve photorefractive ke
Read article...

International Stem Cell Corporation Provides Comments on National Institutes of Health's Proposed Stem Cell Research Guidelines

Press Release Source: International Stem Cell Corporation International Stem Cell Corporation Provides Comments on National Institutes of Health's Proposed Stem Cell Research Guidelines On Tuesday May 19, 2009, 8:30 am EDT OCEANSIDE, Calif.--()--International Stem Cell Corporation (OTCBB:ISCO) (www.intlstemcell.com), the company which pioneered the creation of human stem cells from unfertilized eggs (called “parthenogenetic stem cells”), provides the following comments regarding draft stem cell research guidelines issued by the National Institutes of Health (NIH) on April 17, 200
Read article...

International Stem Cell Corporation Announces the Release of DataTrends Equity Research Group Investor's Corporate Profile® of the Company

Press Release Source: International Stem Cell Corporation International Stem Cell Corporation Announces the Release of DataTrends Equity Research Group Investor's Corporate Profile of the Company ISCO Has Developed Human Stem Cell Lines That Could Potentially Eliminate Problems of Immune Rejection On Thursday May 14, 2009, 11:07 am EDT OCEANSIDE, Calif.--()--International Stem Cell Corporation (OTCBB: ISCO) announced recently that the Data Trends Equity Research Group, a unit of DataTrends Publications, Inc., publisher of Stem Cell Business News
Read article...

International Stem Cell Reports Excellent Preliminary Results for Skin Rejuvenation

Press Release Source: International Stem Cell Corporation International Stem Cell Reports Excellent Preliminary Results for Skin Rejuvenation Skincare Product Resulted from Fundamental Parthenogenic Stem Cell Research Tuesday April 21, 2009, 8:15 am EDT OCEANSIDE, Calif.--()--International Stem Cell Corporation (OTCBB:ISCO) (www.intlstemcell.com), has received excellent preliminary results for a new retail skin rejuvenation product that has been developed as a result of its fundamental research into Parthenogenic Stem Cells.
Read article...

International Stem Cell Reports Excellent Preliminary Results for Skin Rejuvenation

Press Release Source: International Stem Cell Corporation International Stem Cell Reports Excellent Preliminary Results for Skin Rejuvenation Skincare Product Resulted from Fundamental Parthenogenic Stem Cell Research Tuesday April 21, 2009, 8:15 am EDT OCEANSIDE, Calif.--()--International Stem Cell Corporation (OTCBB:ISCO) (www.intlstemcell.com), has received excellent preliminary results for a new retail skin rejuvenation product that has been developed as a result of its fundamental research into Parthenogenic Stem Cells.
Read article...

International Stem Cell Corporation Receives Third $1M Tranche under a $5 Million Financing

(OTCBB:ISCO) International Stem Cell Corp. Press ReleaseSource: International Stem Cell Corporation International Stem Cell Corporation Receives Third $1M Tranche under a $5 Million FinancingTuesday March 17, 8:15 am ET OCEANSIDE, Calif.-International Stem Cell Corporation has received the third $1 million tranche of an anticipated private equity financing of up to $5 million to be funded over the next several months. The total amount of the financing will allow the Company to move forward with the construction of its new cGMP cell culture facility and to continue its therapeutic research, including ongoing pre-clinical trials. The money will also be allocated to fund equipment, product development and marketing requirements to increase revenues in the Company?s subsidiary, Lifeline Cell Technology, which makes and sells s
Read article...

International Stem Cell Corporation Receives Third $1M Tranche under a $5 Million Financing

(OTCBB:ISCO) International Stem Cell Corp. Press ReleaseSource: International Stem Cell Corporation International Stem Cell Corporation Receives Third $1M Tranche under a $5 Million FinancingTuesday March 17, 8:15 am ET OCEANSIDE, Calif.-International Stem Cell Corporation has received the third $1 million tranche of an anticipated private equity financing of up to $5 million to be funded over the next several months. The total amount of the financing will allow the Company to move forward with the construction of its new cGMP cell culture facility and to continue its therapeutic research, including ongoing pre-clinical trials. The money will also be allocated to fund equipment, product development and marketing requirements to increase revenues in the Company?s subsidiary, Lifeline Cell Technology, which makes and sells s
Read article...

International Stem Cell Corporation enters into an Agreement with Cytograft Tissue Engineering to Develop a Therapeutic Medium for Cytograft's Living Vascular Grafts

(OTCBB:ISCO) International Stem Cell Corp. Press ReleaseSource: International Stem Cell Corporation International Stem Cell Corporation enters into an Agreement with Cytograft Tissue Engineering to Develop a Therapeutic Medium for Cytograft's Living Vascular GraftsThursday March 12, 8:15 am ET Living laboratory grown blood vessels from the patient?s own cells OCEANSIDE, Calif.-International Stem Cell Corporation , the first company to perfect a method of creating human ?parthenogenetic? stem cells, which are derived from unfertilized human eggs, is working with tissue engineers at Cytograft Tissue Engineering, , to design a custom cell culture medium to cultivate living human vascular grafts; grafts which are expected to be used in future human clinical trials.
Read article...

International Stem Cell Corporation enters into an Agreement with Cytograft Tissue Engineering to Develop a Therapeutic Medium for Cytograft's Living Vascular Grafts

(OTCBB:ISCO) International Stem Cell Corp. Press ReleaseSource: International Stem Cell Corporation International Stem Cell Corporation enters into an Agreement with Cytograft Tissue Engineering to Develop a Therapeutic Medium for Cytograft's Living Vascular GraftsThursday March 12, 8:15 am ET Living laboratory grown blood vessels from the patient?s own cells OCEANSIDE, Calif.-International Stem Cell Corporation , the first company to perfect a method of creating human ?parthenogenetic? stem cells, which are derived from unfertilized human eggs, is working with tissue engineers at Cytograft Tissue Engineering, , to design a custom cell culture medium to cultivate living human vascular grafts; grafts which are expected to be used in future human clinical trials.
Read article...

International Stem Cell Corporation Applauds President Obama's Decision to Allow Funding of Parthenogenetic Stem Cell Research

(OTCBB:ISCO) International Stem Cell Corp. Press ReleaseSource: International Stem Cell Corporation International Stem Cell Corporation Applauds President Obama's Decision to Allow Funding of Parthenogenetic Stem Cell ResearchTuesday March 10, 8:15 am ET OCEANSIDE, Calif.-International Stem Cell Corporation , the first company to perfect a method of creating human stem cells from unfertilized eggs, applauds President Obama?s signing of an executive order to allow funding of stem cell research. ISCO?s unique human stem cells, called ?parthenogenetic? stem cells, have ethical advantages since they do not harm a viable human embryo and have medical advantages since they can be immune matched to hundreds of millions of people across the world.
Read article...

International Stem Cell Corporation Applauds President Obama's Decision to Allow Funding of Parthenogenetic Stem Cell Research

(OTCBB:ISCO) International Stem Cell Corp. Press ReleaseSource: International Stem Cell Corporation International Stem Cell Corporation Applauds President Obama's Decision to Allow Funding of Parthenogenetic Stem Cell ResearchTuesday March 10, 8:15 am ET OCEANSIDE, Calif.-International Stem Cell Corporation , the first company to perfect a method of creating human stem cells from unfertilized eggs, applauds President Obama?s signing of an executive order to allow funding of stem cell research. ISCO?s unique human stem cells, called ?parthenogenetic? stem cells, have ethical advantages since they do not harm a viable human embryo and have medical advantages since they can be immune matched to hundreds of millions of people across the world.
Read article...

International Stem Cell Corporation Hosts Webinar, "Stem Cells 102: Beyond Embryonic Stem Cell Research," Thursday, March 12, 2009, From 1:00pm-2:00pm EDT

(OTCBB:ISCO) International Stem Cell Corp. Press ReleaseSource: International Stem Cell Corporation International Stem Cell Corporation Hosts Webinar, "Stem Cells 102: Beyond Embryonic Stem Cell Research," Thursday, March 12, 2009, From 1:00pm-2:00pm EDTFriday March 6, 8:15 am ET Free Educational Webinar for Journalists, Shareholders, and Investment Professionals OCEANSIDE, Calif.-International Stem Cell Corporation , the first company to perfect a method of creating human ?parthenogenetic? stem cells from unfertilized eggs, will host a webinar titled ?Stem Cells 102: Beyond Embryonic Stem Cell Research,? Thursday, March 12, 2009, from 1:00pm-2:00pm EDT. This free educational webinar is for journalists, shareholders, and investment professionals interested in learning about new emerging technology
Read article...

DiscoveryBioMed, Inc. Engaged in Multiple Projects on Behalf of Lifeline Cell Technology, Inc. to Test the Function and Utility of Multiple Primary Human Cell Products

(OTCBB:ISCO) International Stem Cell Corp. Press ReleaseSource: International Stem Cell Corporation DiscoveryBioMed, Inc. Engaged in Multiple Projects on Behalf of Lifeline Cell Technology, Inc. to Test the Function and Utility of Multiple Primary Human Cell ProductsThursday February 19, 8:15 am ET Lifeline Cell Technology Products Being Used As Models for Drug Testing BIRMINGHAM, Ala. & OCEANSIDE, Calif.-DiscoveryBioMed, Inc. has agreed to move forward with a ?service? contract for primary human cell bioassay testing for its first commercial client, Lifeline Cell Technology, Inc., a wholly owned subsidiary of International Stem Cell Corporation . ?This is a mutually ben
Read article...

International Stem Cell Corporation Issues Letter to Shareholders

(OTCBB:ISCO) International Stem Cell Corp. Press ReleaseSource: International Stem Cell Corporation International Stem Cell Corporation Issues Letter to ShareholdersThursday February 5, 8:15 am ET Letter Describes Changing Political Climate, Competitive Advantages of Parthenogenesis, Creation of Human Corneal Tissue, New Partnerships, Clinical Trials, and Other Developments OCEANSIDE, Calif.-International Stem Cell Corporation , the first company to perfect a method of creating human stem cells from unfertilized eggs, has issued a letter to its shareholders. To view the shareholder letter in its entirety, please follow the link to the company?s website: http://www.internationalstemcell.com/shareholderletter.htm.The Letter covers a variety of subjects, including:
Read article...

International Stem Cell Corporation Featured In The Economist

(OTCBB:ISCO) International Stem Cell Corp. Press ReleaseSource: International Stem Cell Corporation International Stem Cell Corporation Featured In The EconomistTuesday February 3, 8:15 am ET Article Details ISCOs Solutions To Ethical And Immune Rejection Issues OCEANSIDE, Calif.-International Stem Cell Corporation , the first company to perfect a method of creating human ?parthenogenetic? stem cells from unfertilized eggs, has been featured in the January 31, 2009, edition of The Economist, the authoritative weekly publication focusing on international politics and business news and opinion. The article, titled ?Embryonic Stem Cells: Can I Serve You Now?,? details how ISCO?s unique parthenogenetic approach helps resolve two of t
Read article...

International Stem Cell Corporation Featured In The Economist

(OTCBB:ISCO) International Stem Cell Corp. Press ReleaseSource: International Stem Cell Corporation International Stem Cell Corporation Featured In The EconomistTuesday February 3, 8:15 am ET Article Details ISCOs Solutions To Ethical And Immune Rejection Issues OCEANSIDE, Calif.-International Stem Cell Corporation , the first company to perfect a method of creating human ?parthenogenetic? stem cells from unfertilized eggs, has been featured in the January 31, 2009, edition of The Economist, the authoritative weekly publication focusing on international politics and business news and opinion. The article, titled ?Embryonic Stem Cells: Can I Serve You Now?,? details how ISCO?s unique parthenogenetic approach helps resolve two of the conundrums that have long shadowed stem c
Read article...

StemCellPatents.com Applauds International Stem Cell Corporation (ISCO) on Recent Developments

(OTCBB:ISCO) International Stem Cell Corp. Press ReleaseSource: StemCellPatents.com StemCellPatents.com Applauds International Stem Cell Corporation on Recent DevelopmentsFriday January 30, 3:35 am ET ISCO First to Grow Human Corneal Tissue from Stem Cells, Entering Pre-Clinical Trials for Retinal Disease & Improved Forms of Corrective Laser Eye Surgery SAN DIEGO-StemCellPatents.com, an organization that covers recent news in stem cell therapeutics and has assembled the only comprehensive index of all issued U.S. stem cell patents, congratulates International Stem Cell Corporation on its recent developments, including being the first company to grow human corneal tissue from stem cells. ISCO, the first company
Read article...

International Stem Cell Corporation Begins Pre-Clinical Trials on Human Corneal Epithelial Cells

(OTCBB:ISCO) International Stem Cell Corp. Press ReleaseSource: International Stem Cell Corporation International Stem Cell Corporation Begins Pre-Clinical Trials on Human Corneal Epithelial CellsThursday January 29, 8:15 am ET Trials Designed to Improve Laser Eye Surgery Outcomes OCEANSIDE, Calif.-International Stem Cell Corporation , the first company to perfect a method of creating human ?parthenogenetic? stem cells from unfertilized eggs, is planning pre-clinical trials aimed at applying its laboratory-grown human corneal epithelial cells to improve photorefractive keratectomy , a form of corrective laser eye surgery. These trials are the first step toward Food and Drug Administration clinical trials to test the efficacy of using ISCO cel
Read article...

International Stem Cell Corporation Begins Pre-Clinical Trials on Human Corneal Epithelial Cells

(OTCBB:ISCO) International Stem Cell Corp. Press ReleaseSource: International Stem Cell Corporation International Stem Cell Corporation Begins Pre-Clinical Trials on Human Corneal Epithelial CellsThursday January 29, 8:15 am ET Trials Designed to Improve Laser Eye Surgery Outcomes OCEANSIDE, Calif.-International Stem Cell Corporation , the first company to perfect a method of creating human ?parthenogenetic? stem cells from unfertilized eggs, is planning pre-clinical trials aimed at applying its laboratory-grown human corneal epithelial cells to improve photorefractive keratectomy , a form of corrective laser eye surgery. These trials are the first step toward Food and Drug Administration clinical trials to test the effic
Read article...

International Stem Cell Begins Pre-Clinical Testing of Its Parthenogenetic Stem Cells for Treatment of Retinal Disease

(OTCBB:ISCO) International Stem Cell Corp. Press ReleaseSource: International Stem Cell Corporation International Stem Cell Begins Pre-Clinical Testing of Its Parthenogenetic Stem Cells for Treatment of Retinal DiseaseTuesday January 13, 8:15 am ET First Company To Grow Human Corneal Tissue From Stem Cells OCEANSIDE, Calif.-International Stem Cell Corporation has created layered human tissue from its unique parthenogenetic stem cells and transplanted this tissue into animals in pre-clinical trials to establish a potential new treatment for human retinal diseases, such as macular degeneration or retinitis pigmentosa. ?Intact layers of retinal progenitor cells have been shown to restore lost visual responses in several re
Read article...

International Stem Cell Corporation Discusses Recent Funding

(OTCBB:ISCO) International Stem Cell Corp. Press ReleaseSource: International Stem Cell Corporation International Stem Cell Corporation Discusses Recent FundingMonday January 5, 8:15 am ET OCEANSIDE, Calif.-International Stem Cell Corporation announced on December 30 that it had received the first $1 million tranche of an anticipated private equity financing of up to $5 million to be funded over the next several months. Officials of the Company commented recently on the significance of that funding. ?This is a first major step toward the Company?s goal of becoming financially self-sufficient,? said Kenneth Aldrich, CEO of the Company. Mr. Aldrich noted that the anticipated $5 million of funding is targeted toward three
Read article...

International Stem Cell Corporation Closes Financing

(OTCBB:ISCO) International Stem Cell Corp. Press ReleaseSource: International Stem Cell Corporation International Stem Cell Corporation Closes FinancingTuesday December 30, 12:24 pm ET OCEANSIDE, Calif.-International Stem Cell Corporation announced recently that it had received the first $1 million tranche of an anticipated private equity financing of up to $5 million to be funded over the next several months. The total amount of the financing is intended to allow the Company to retire its existing secured debt and fund operations of the Company as it moves forward with planned pre-clinical trials in the first quarter of 2009. ?This is an important vote of confidence by a sophisticated investor group and we believe it is a major first step on the path to making our company financially independent,? said Kenneth Aldrich, CEO of t
Read article...

International Stem Cell Corporation Partners with Absorption Systems to Commercialize Human Stem Cell-Derived Corneal Tissue for Drug Testing

(OTCBB:ISCO) International Stem Cell Corp. Press ReleaseSource: International Stem Cell Corporation International Stem Cell Corporation Partners with Absorption Systems to Commercialize Human Stem Cell-Derived Corneal Tissue for Drug TestingMonday November 24, 8:15 am ET OCEANSIDE, Calif. & EXTON, Pa.-International Stem Cell Corporation , the first company to perfect a method of creating human ?parthenogenetic? stem cells from unfertilized eggs, has formed a partnership with Absorption Systems to utilize ISCO?s parthenogenetic stem cell-derived human corneal tissue to measure drug disposition, drug safety and drug-drug interactions. The collaboration between the companies is focused on using Absorption Systems? know how in creating in vitro assay systems to develop a superior method of testing drugs that will also reduce
Read article...

Stem Cells, Reborn

(OTCBB:ISCO) International Stem Cell Corp. Press ReleaseSource: International Stem Cell Corporation Stem Cells, RebornThursday November 13, 4:35 am ET -In the emerging field of regenerative medicine one topic that has earned its fair share of notoriety is the issue of embryonic stem cell research. Stem cells are characterized by the ability to renew themselves through cell division and differentiate into a diverse range of specialized cell types. Since stem cells can be grown and transformed into specialized cells with characteristics consistent with various tissue such as muscles or nerves, their use in medical therapies has been prized. The goal of any stem cell therapy is to repair damaged tissue that can?t heal itself, which might be accomplished by transplanting stem cells into damaged areas and directing them to grow new,
Read article...

Stem Cells, Reborn

(OTCBB:ISCO) International Stem Cell Corp. Press ReleaseSource: International Stem Cell Corporation Stem Cells, RebornThursday November 13, 4:35 am ET -In the emerging field of regenerative medicine one topic that has earned its fair share of notoriety is the issue of embryonic stem cell research. Stem cells are characterized by the ability to renew themselves through cell division and differentiate into a diverse range of specialized cell types. Since stem cells can be grown and transformed into specialized cells with characteristics consistent with various tissue such as muscles or nerves, their use in medical therapies has been prized. The goal of any stem cell therapy is to repair damaged tissue that can?t heal itself, which might be accomplished by transplanting stem cells into damaged areas and directing them to grow new,
Read article...

International Stem Cell Corporation Releases Letter to Shareholders

(OTCBB:ISCO) International Stem Cell Corp. Press ReleaseSource: International Stem Cell Corporation International Stem Cell Corporation Releases Letter to ShareholdersThursday October 23, 7:00 am ET Letter Describes Human Parthenogenetic Stem Cell Company's Distinct Science and Business Model OCEANSIDE, Calif.-International Stem Cell Corporation , the first company to perfect a method of creating human stem cells from unfertilized eggs, has issued a letter to its shareholders. To view the shareholder letter in its entirety, please follow the link to the company?s website: www.internationalstemcell.com/shareholderletter.htm.In the letter, International Stem Cell CEO, Ken Aldrich, updates shareholders on the company?s continued efforts to increase shareholder value related to its key initiatives, which include:
Read article...

International Stem Cell Corporation Releases Letter to Shareholders

(OTCBB:ISCO) International Stem Cell Corp. Press ReleaseSource: International Stem Cell Corporation International Stem Cell Corporation Releases Letter to ShareholdersThursday October 23, 7:00 am ET Letter Describes Human Parthenogenetic Stem Cell Company's Distinct Science and Business Model OCEANSIDE, Calif.-International Stem Cell Corporation , the first company to perfect a method of creating human stem cells from unfertilized eggs, has issued a letter to its shareholders. To view the shareholder letter in its entirety, please follow the link to the company?s website: www.internationalstemcell.com/shareholderletter.htm.In the letter, International Stem Cell CEO, Ken Aldrich, updates shareholders on the company?s continued efforts to increase shareholder value related to its key initiatives, which include:
Read article...

International Stem Cell Corporation Retains The Investor Relations Group

(OTCBB:ISCO) International Stem Cell Corp. Press ReleaseSource: International Stem Cell Corporation International Stem Cell Corporation Retains The Investor Relations GroupWednesday October 22, 2:54 pm ET Active Investor and Media Outreach to Build Company Awareness as a Leading Parthenogenetic Stem Cell Company OCEANSIDE, Calif.-International Stem Cell Corporation , the first company to perfect a method of creating human stem cells from unfertilized eggs, has retained the Investor Relations Group , a highly recognized corporate communications firm based in New York City, to serve as its national investor and public relations firm. International Stem Cell is the first company to perfect a method of creating human stem cells from unfertilized
Read article...

International Stem Cell Corporation Names Rouslan Semechkin to Board of Directors

(OTCBB:ISCO) International Stem Cell Corp. Press ReleaseSource: International Stem Cell Corporation International Stem Cell Corporation Names Rouslan Semechkin to Board of DirectorsThursday October 16, 9:30 am ET OCEANSIDE, Calif.-International Stem Cell Corporation , a California-based, early-stage stem cell therapeutics company, announced recently that Rouslan Semechkin has joined its Board of Directors. International Stem Cell Corporation?s focus is on the development of stem cell based treatment of diabetes, liver disease and diseases of the retina and providing specialized cells and media to others for cell based research. It maintains corporate and research facilities in Oceanside, California; production and product development in Walk
Read article...